| pubmed-article:17551300 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:17551300 | lifeskim:mentions | umls-concept:C0007634 | lld:lifeskim |
| pubmed-article:17551300 | lifeskim:mentions | umls-concept:C0684249 | lld:lifeskim |
| pubmed-article:17551300 | lifeskim:mentions | umls-concept:C0034656 | lld:lifeskim |
| pubmed-article:17551300 | lifeskim:mentions | umls-concept:C0007131 | lld:lifeskim |
| pubmed-article:17551300 | lifeskim:mentions | umls-concept:C0442027 | lld:lifeskim |
| pubmed-article:17551300 | lifeskim:mentions | umls-concept:C1522484 | lld:lifeskim |
| pubmed-article:17551300 | lifeskim:mentions | umls-concept:C0078257 | lld:lifeskim |
| pubmed-article:17551300 | lifeskim:mentions | umls-concept:C0036525 | lld:lifeskim |
| pubmed-article:17551300 | lifeskim:mentions | umls-concept:C0450442 | lld:lifeskim |
| pubmed-article:17551300 | lifeskim:mentions | umls-concept:C0013125 | lld:lifeskim |
| pubmed-article:17551300 | lifeskim:mentions | umls-concept:C0282460 | lld:lifeskim |
| pubmed-article:17551300 | lifeskim:mentions | umls-concept:C1708063 | lld:lifeskim |
| pubmed-article:17551300 | lifeskim:mentions | umls-concept:C0205171 | lld:lifeskim |
| pubmed-article:17551300 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:17551300 | pubmed:dateCreated | 2007-6-6 | lld:pubmed |
| pubmed-article:17551300 | pubmed:abstractText | Many patients with metastatic nonsmall cell lung carcinoma (NSCLC) cannot tolerate intravenous chemotherapy. Orally active agents would be more convenient and thus could improve their quality of life. | lld:pubmed |
| pubmed-article:17551300 | pubmed:language | eng | lld:pubmed |
| pubmed-article:17551300 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17551300 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:17551300 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17551300 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17551300 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17551300 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:17551300 | pubmed:month | Jun | lld:pubmed |
| pubmed-article:17551300 | pubmed:issn | 1537-453X | lld:pubmed |
| pubmed-article:17551300 | pubmed:author | pubmed-author:NguyenLaurent... | lld:pubmed |
| pubmed-article:17551300 | pubmed:author | pubmed-author:LeopoldLance... | lld:pubmed |
| pubmed-article:17551300 | pubmed:author | pubmed-author:RigasJames... | lld:pubmed |
| pubmed-article:17551300 | pubmed:author | pubmed-author:JahanzebMoham... | lld:pubmed |
| pubmed-article:17551300 | pubmed:author | pubmed-author:HirshVeraV | lld:pubmed |
| pubmed-article:17551300 | pubmed:author | pubmed-author:DesjardinsPie... | lld:pubmed |
| pubmed-article:17551300 | pubmed:author | pubmed-author:NeedlesBurton... | lld:pubmed |
| pubmed-article:17551300 | pubmed:author | pubmed-author:ZembrykiDenis... | lld:pubmed |
| pubmed-article:17551300 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:17551300 | pubmed:volume | 30 | lld:pubmed |
| pubmed-article:17551300 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:17551300 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:17551300 | pubmed:pagination | 245-51 | lld:pubmed |
| pubmed-article:17551300 | pubmed:meshHeading | pubmed-meshheading:17551300... | lld:pubmed |
| pubmed-article:17551300 | pubmed:meshHeading | pubmed-meshheading:17551300... | lld:pubmed |
| pubmed-article:17551300 | pubmed:meshHeading | pubmed-meshheading:17551300... | lld:pubmed |
| pubmed-article:17551300 | pubmed:meshHeading | pubmed-meshheading:17551300... | lld:pubmed |
| pubmed-article:17551300 | pubmed:meshHeading | pubmed-meshheading:17551300... | lld:pubmed |
| pubmed-article:17551300 | pubmed:meshHeading | pubmed-meshheading:17551300... | lld:pubmed |
| pubmed-article:17551300 | pubmed:meshHeading | pubmed-meshheading:17551300... | lld:pubmed |
| pubmed-article:17551300 | pubmed:meshHeading | pubmed-meshheading:17551300... | lld:pubmed |
| pubmed-article:17551300 | pubmed:meshHeading | pubmed-meshheading:17551300... | lld:pubmed |
| pubmed-article:17551300 | pubmed:meshHeading | pubmed-meshheading:17551300... | lld:pubmed |
| pubmed-article:17551300 | pubmed:meshHeading | pubmed-meshheading:17551300... | lld:pubmed |
| pubmed-article:17551300 | pubmed:meshHeading | pubmed-meshheading:17551300... | lld:pubmed |
| pubmed-article:17551300 | pubmed:meshHeading | pubmed-meshheading:17551300... | lld:pubmed |
| pubmed-article:17551300 | pubmed:year | 2007 | lld:pubmed |
| pubmed-article:17551300 | pubmed:articleTitle | Oral versus intravenous administration of vinorelbine as a single agent for the first-line treatment of metastatic nonsmall cell lung carcinoma (NSCLC): A randomized phase II trial. | lld:pubmed |
| pubmed-article:17551300 | pubmed:affiliation | Royal Victoria Hospital, McGill University, Montreal, Quebec, Canada. vera.hirsh@muhc.mcgill.ca | lld:pubmed |
| pubmed-article:17551300 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:17551300 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:17551300 | pubmed:publicationType | Clinical Trial, Phase II | lld:pubmed |
